Best of Oncology – Best of Oncology

Tri-State ASCO Direct™

Oncology Highlights Conference

November 2, 2024 | The Summit Hotel

Powered by Cincinnati Cancer Advisors

00Days
00Hours
00Min
00Sec

About our 2024 Highlights Conference

Best of Oncology is the “ASCO Direct™” licensed event for the tri-state that will highlight abstracts and educational updates from the 2024 ASCO Annual Meeting. Cincinnati Cancer Advisors created a custom program that promises to meet the needs of the
entire oncology team.

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Current Concepts Institute and Cincinnati Cancer Advisors. The Current Concepts Institute is accredited by the ACCME to provide continuing medical education for physicians.

The Current Concepts institute designates this live activity for a maximum of 6.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Purpose

The ASCO Direct™ program is designed to provide clinicians with key practice-changing data and clinicians and patients with information on other emerging topics from the leading clinical oncology event in the United States, ASCO Annual 2024.

Speakers

Learn from leading experts about breast and gynecological cancers, lung cancer, melanoma, sarcoma, GI malignancies and hematology discussing recent clinical trial findings that have the potential to change clinical practices and optimize outcomes.

Committee

The event is sponsored by Cincinnati Cancer Advisors (CCA) and is being held for the second time in Cincinnati thanks to the effort by many prestigious individuals and leaders who are passionate about having platinum level care in the Cincinnati region.

Great Care Begins with a Great Plan

Cincinnati Cancer Advisors is an independent group that exists to improve the care of cancer patients who are seeking an objective second opinion. Our mission is to deliver a thorough understanding of diagnoses and confidence in a plan of care without assuming care of the patient. We aim to take the feelings of chaos and financial insecurity out of a cancer diagnosis and make second opinions and world-class care more accessible.

Conference Sessions

Each session covers abstracts presented on a specific disease state or therapy from the 2024 ASCO Annual Meeting, summarize the presented information's impact on practice, and explore a case vignette illustrating the implications of the new data on patient care and treatment. Following each expert faculty's presentation there was an opportunity for learners to participate in Q&A with the speakers and moderators.

2022 Speaker Highlights

These speakers broke down key takeaways from ASCO 2022

Ghassan Abou-Alfa is an Attending Physician at Memorial Sloan Kettering Cancer Center (MSK) and Professor of Medicine at Weill Medical School at Cornell University. Professor Abou-Alfa specializes in in the treatment of gastrointestinal malignancies and in particular, hepatocellular carcinoma (HCC), intrahepatic and extrahepatic cholangiocarcinoma (IHC), gallbladder cancer (GB), and fibrolamellar carcinoma (FLC).

Alex A. Adjei is Chairman of the Taussig Cancer Institute and the M. Frank Rudy and Margaret D. Rudy Distinguished Chair in Translational Cancer Research at Cleveland Clinic. He received the first American Society of Clinical Oncology Drug Development Research Professorship 2012-2017, in recognition of his mentorship and work in cancer drug development.

Dr. Barbara Burtness is Professor of Medicine at the Yale University School of Medicine, Interim Associate Cancer Center Director, Diversity, Equity, and Inclusion; Disease Aligned Research Team Leader, Head and Neck Cancers Program; Co-Leader, Developmental Therapeutics, Yale Cancer Center; and Director of the Yale Head and Neck SPORE. Dr. Burtness’ research focuses on translational studies in head and neck cancer, including biomarkers of resistance to EGFR inhibition and synthetic lethal approaches for HPV negative head and neck cancer.

Ian W. Flinn, MD, PhD. is the Director of Lymphoma Research at the Sarah Cannon Research Institute. In this role, he oversees lymphoma research throughout Sarah Cannon and its affiliates. Dr. Flinn also serves as the Director for the Sarah Cannon Center for Blood Cancer at Tennessee Oncology. Dr. Flinn’s research focuses on the development of new therapies for patients with lymphoma and chronic lymphocytic leukemia. This research includes first in human to phase 3 trials with novel approaches such as immune effector cell therapies, inhibitors of the B cell receptor pathway, and BCL-2 inhibitors amongst others.

Dr. Christopher J. Logothetis has a longstanding interest in genitourinary cancers—germ cell tumors, bladder, renal, and most recently in his career, prostate cancer. His research experience preceded the development of effective chemotherapy and extends to the current era of molecular targeted therapies and classification of cancer. He was among the first to test chemotherapy agents at a time of general skepticism that chemotherapy would be useful in advanced prostate cancer.

Kathy D. Miller received her MD in 1991 from the Johns Hopkins School of Medicine in Baltimore, MD. Dr. Miller completed internal medicine training at Hopkins, then returned to her native Midwest for fellowship training at Indiana University, serving as Chief Fellow in 1997. She returned to Indiana University in 1999, attaining the rank of Professor and Ballvé-Lantero Scholar in 2014.

Michael Postow is a medical oncologist who cares exclusively for patients with advanced melanoma seeking discussions about systemic treatments. He is the Chief of the Melanoma Service at Memorial Sloan Kettering Cancer Center where he leads a group of six faculty physicians dedicated to the care and research of patients with melanoma. His prior work leading the first randomized trial of combined immune checkpoint inhibition (nivolumab + ipilimumab) resulted in its FDA approval in 2015, and he has led several other investigator-initiated trials of immunotherapy combinations.